Chardan Capital Resumes La Jolla Pharma (LJPC) at Buy; Sees Sales Over $1B by FY22
Tweet Send to a Friend
La Jolla Pharmaceutical (Nasdaq: LJPC) is confidently higher Mondayas Chardan Capital resumed coverage on the stock with a Buy rating ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE